Increased levels of serum NfL at baseline were associated with higher risk of developing brain atrophy in the following 2 years, suggesting that serum NfL may be used as a new indicator of early neuroaxonal injury in MS patients (Siller et al., 2019[98]). Here, NEFL is linked to myeloid sarcoma.